Source comparison
MK-677 Side Effects Studies: Comparison Table
Elevated fasting glucose 60–70% (mean +0.3–0.5 mmol/L) GH-mediated hepatic gluconeogenesis + impaired peripheral glucose uptake Reverses 2–4 weeks post-discontinuation in short-term use; partial persistence in long-term use Low in metabolically healthy adults;
This comparison does not assign a generated winner or score.
- Elevated fasting glucose
- 60–70% (mean +0.3–0.5 mmol/L)
- GH-mediated hepatic gluconeogenesis + impaired peripheral glucose uptake
- Reverses 2–4 weeks post-discontinuation in short-term use; partial persistence in long-term use
- Low in metabolically healthy adults; moderate-high in pre-diabetic or insulin-resistant individuals
- Peripheral edema
- 30–40% (mild lower-extremity swelling)
- GH-induced renal sodium reabsorption via ENaC upregulation
- Resolves spontaneously within 4–12 weeks as ANP/BNP compensate
- Low—transient cosmetic concern, not indicative of organ dysfunction
- Increased appetite
- 50–65% (mean +200–400 kcal/day intake)
- Ghrelin receptor (GHS-R1a) activation in hypothalamic arcuate nucleus
- Reverses within 48–72 hours of discontinuation
- Moderate—complicates caloric deficit protocols; neutral or beneficial in muscle-building contexts
- Transient cortisol elevation
- 40–50% (15–25% above baseline, peak 2–4h post-dose)
- GH-stimulated ACTH release from anterior pituitary
- Returns to baseline within 8–12 hours; no sustained hypercortisolemia
- Low—peak elevations remain within physiological range
- Mild prolactin increase
- 30–40% (transient elevation 2–4h post-dose)
- GH cross-activation of lactotroph receptors in pituitary
- Returns to baseline within 8–12 hours; no chronic hyperprolactinemia
- Low—no documented cases of gynecomastia or galactorrhea at standard doses